ArticleOncology letters2015
CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- DPP4, a potential tumor biomarker, and tumor therapeutic target: review.Molecular biology reports · 2025Review
- Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.Cancers · 2024Review
- Multiparameter flow cytometric detection and analysis of rare cells inBiology methods & protocols · 2024Article
- Correlation analysis of the expression of mesenchymal circulating tumor cells and CD133 with the prognosis of colorectal cancer.American journal of translational research · 2023Article
- CD26 Induces Colorectal Cancer Angiogenesis and Metastasis through CAV1/MMP1 Signaling.International journal of molecular sciences · 2022Article
- Flow cytometry-based analysis of tumor-leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer.Cytometry. Part B, Clinical cytometry · 2021Article
- Molecular features and gene expression signature of metastatic colorectal cancer (Review).Oncology reports · 2021Review
- In silico Analysis, Molecular Docking, Molecular Dynamic, Cloning, Expression and Purification of Chimeric Protein in Colorectal Cancer Treatment.Drug design, development and therapy · 2020Article
- Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26Biology open · 2019Article
- Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.Ecancermedicalscience · 2019Article
- Multifaceted Interpretation of Colon Cancer Stem Cells.International journal of molecular sciences · 2017Review
- Suppression of CD26 inhibits growth and metastasis of pancreatic cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- DPPIV/CD26: a tumor suppressor or a marker of malignancy?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Circulating tumor cells in head and neck cancer: A review.World journal of otorhinolaryngology - head and neck surgery · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study evaluated the presence and clinical relevance of a cluster of differentiation (CD)26
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.